- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 40/42 - Antigènes associés au cancer
Détention brevets de la classe A61K 40/42
Brevets de cette classe: 1229
Historique des publications depuis 10 ans
|
0
|
0
|
1
|
7
|
22
|
69
|
96
|
39
|
37
|
682
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Regents of the University of California | 20211 |
30 |
| The Trustees of the University of Pennsylvania | 4377 |
28 |
| Memorial Sloan-Kettering Cancer Center | 1970 |
21 |
| Board of Regents, The University of Texas System | 5912 |
20 |
| Kite Pharma, Inc. | 409 |
19 |
| Dana-Farber Cancer Institute, Inc. | 2613 |
15 |
| Juno Therapeutics, Inc. | 446 |
15 |
| Fred Hutchinson Cancer Center | 460 |
15 |
| The General Hospital Corporation | 4794 |
14 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 979 |
14 |
| The Board of Trustees of the Leland Stanford Junior University | 6507 |
13 |
| Autolus Limited | 259 |
13 |
| Iovance Biotherapeutics, Inc. | 345 |
13 |
| Memorial Hospital for Cancer and Allied Diseases | 316 |
13 |
| FATE Therapeutics, Inc. | 212 |
12 |
| Immatics Biotechnologies GmbH | 1155 |
12 |
| Sloan-Kettering Institute for Cancer Research | 537 |
12 |
| Immunitybio, Inc. | 454 |
12 |
| Novartis AG | 10674 |
11 |
| Takeda Pharmaceutical Company Limited | 2713 |
10 |
| Autres propriétaires | 917 |